Erasca, Inc. Common Stock
ERASErasca, Inc. is a biotechnology company focused on developing targeted therapies for cancer treatment. The company specializes in utilizing genomic and proteomic data to identify and develop personalized medicines for patients with various types of cancer. It aims to advance precision oncology through innovative drug discovery and development strategies.
Company News
Rosen Law Firm is reminding investors who purchased Erasca, Inc. common stock between January 14, 2025 and April 26, 2026 of an August 10, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Erasca and its executives made false and misleading statements about its lead oncology drug candidate ERAS-0015, including impr...
Kahn Swick & Foti, LLC announces a class action securities lawsuit against Erasca, Inc. for investors who purchased shares between January 14, 2025 and April 26, 2026. The lawsuit alleges that Erasca and its executives failed to disclose material information, including that preclinical data for ERAS-0015 was based on improper comparisons and plac...
Erasca, Inc. faces a securities class action lawsuit alleging that CEO Jonathan Lim and CFO David Chacko certified misleading statements about the ERAS-0015 drug trial while the company raised $258.8 million from investors. The stock collapsed 53.9% after disclosures revealed patent infringement allegations and a patient death. The lead plaintiff...
Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers, announced the pricing of an upsized public offering of 31.4 million shares at $17.50 per share, generating approximately $550 million in gross proceeds. The offering is expected to close on July 15, 2026, with proceeds to be used f...
A class action lawsuit has been filed against Erasca, Inc. alleging that the company and its executives made false and misleading statements regarding its ERAS-0015 drug candidate. The lawsuit claims preclinical data was based on improper comparisons to Revolution Medicines and lacked reasonable basis. Following disclosure of a patent infringemen...
